ArticleCureus2026
Paroxysmal Nocturnal Hemoglobinuria in a Young Adult Woman: A Representative Case of Recurrent Intravascular Hemolysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis, hemoglobinuria, bone marrow failure, and an increased risk of thrombosis. We report the case of a 39-year-old woman with iron-deficiency anemia unresponsive to oral therapy who presented with three weeks of dark urine and progressive fatigue. Physical examination revealed pallor and mild scleral icterus. Laboratory evaluation demonstrated severe intravascular hemolysis with markedly elevated lactate dehydrogenase, indirect hyperbilirubinemia, undetectable haptoglobin, and a negative direct Coombs test. Urinalysis showed a positive dipstick for blood without erythrocytes on microscopy, consistent with pigmenturia. High-sensitivity flow cytometry confirmed large PNH clones across all cell lineages. Eculizumab therapy was initiated, resulting in the resolution of hemoglobinuria and improvement in hemoglobin levels and symptoms. This case highlights the importance of considering PNH in patients with Coombs-negative hemolytic anemia and recurrent dark urine. Early recognition and timely complement inhibition are essential to reducing hemolysis, preventing thrombosis, and optimizing long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.